Patents for A61P 35 - Antineoplastic agents (221,099)
02/2002
02/21/2002US20020022017 Antitumor agents; fusion protein containing colony stimulanting factor
02/21/2002US20020022003 Method and composition for the treatment of cancer by the enzymantic conversion of soluble radioactive toxic precipitates in the cancer
02/21/2002DE10114106C1 New quaternary ammonio-substituted orthosilicate esters, useful as anticancer agents having strong activity against a broad spectrum of human tumor cell lines
02/21/2002DE10039998A1 Neue substituierte Diareno-azepin-Derivate als Integrin Liganden New substituted Diareno-azepine derivatives as integrin ligands
02/21/2002DE10038639A1 New and known N-aryl 2-hydroxy-omega-arylalkanamide derivatives, useful e.g. for treating inflammatory diseases such as rheumatism
02/21/2002CA2804958A1 Therapeutic methods for treating subjects with a recombinant erythropoietin having high activity and reduced side effects
02/21/2002CA2431954A1 A retroviral immunotherapy
02/21/2002CA2420032A1 Oral delivery of peptide
02/21/2002CA2419985A1 Modulating multiple lineage kinase proteins
02/21/2002CA2419790A1 System for regulating in vivo the expression of a transgene by conditional inhibition
02/21/2002CA2419533A1 Compositions and methods for the therapy and diagnosis of her-2/neu-associated malignancies
02/21/2002CA2419491A1 Leucine-rich repeat-containing g-protein coupled receptor-8 molecules and uses thereof
02/21/2002CA2419133A1 Expression of herstatin, an alternative her-2/neu product, in cells that express either p185her-2 or the egf receptor inhibits receptor activity and cell growth
02/21/2002CA2418988A1 Treatment of tumors with acetylenes distributed with a phenyl or heteroaromatic group and a substituted chromanyl, thiochromanyl or tetrahydroquinolinyl group in combination with other anti-tumor agents
02/21/2002CA2418982A1 Chelerythrine-based therapies for cancer
02/21/2002CA2418725A1 Claudin polypeptides
02/21/2002CA2418531A1 Therapeutic methods for treating subjects with a recombinant erythropoietin having high activity and reduced side effects
02/21/2002CA2418389A1 Pyridine derivatives as inhibitors of p38
02/21/2002CA2418320A1 The anti-neoplastic agent et-743 inhibits trans activation by sxr
02/21/2002CA2418303A1 Treatment of hiv-1 infection and inflammatory disease using cyclophilin receptor antagonists
02/21/2002CA2418273A1 Urea compounds and methods of uses
02/21/2002CA2418266A1 Novel mitogen activated kinase
02/21/2002CA2417152A1 Therapeutic compounds for ovarian cancer
02/21/2002CA2416898A1 Method and composition for altering a b cell mediated pathology
02/21/2002CA2416794A1 Method and composition for altering a t cell mediated pathology
02/21/2002CA2387002A1 Non-covalent inhibitors of urokinase and blood vessel formation
02/20/2002EP1180239A2 Methods, pharmaceutical formulations and kits for identification of subjects at risk for cancer
02/20/2002EP1180151A2 Protein kinases
02/20/2002EP1180148A1 A VARIANT OF C6 BETA-CHEMOKINE LEUKOTACTIN-1(shLkn-1) WITH ENHANCED BIOLOGICAL ACTIVITY
02/20/2002EP1180144A2 Cytoskeleton-associated proteins
02/20/2002EP1180123A1 Immunoconjugates having high binding affinity
02/20/2002EP1180116A2 Fap-activated anti-tumor compounds
02/20/2002EP1180113A1 Oligonucleotides having a-dna form and b-dna form conformational geometry
02/20/2002EP1180109A1 Prodrug activation using catalytic antibodies
02/20/2002EP1180105A2 Substituted aza-oxindole derivatives
02/20/2002EP1180100A2 Heterosubstituted pyridine derivatives as pde 4 inhibitors
02/20/2002EP1180053A1 Remote and local controlled delivery of pharmaceutical compounds using electromagnetic energy
02/20/2002EP1180042A1 Model membrane systems
02/20/2002EP1180037A2 Therapeutic uses of agents that modulate the activity of alpha-smooth muscle actin
02/20/2002EP1180035A1 NON-CALCEMIC, ANTIPROLIFERATIVE, TRANSCRIPTIONALLY ACTIVE SULFUR-CONTAINING ANALOGS OF 1$g(a), 25-DIHYDROXY VITAMIN D 3?
02/20/2002EP1180034A1 Novel epidermal growth factor receptor-binding compounds for positron emission tomography
02/20/2002EP1180026A2 Use of 15-deoxyspergualin for the treatment of hyperreactive inflammatory diseases and autoimmune diseases
02/20/2002EP1180024A1 Z-styryl sulfone anticancer agents
02/20/2002EP1180016A2 Methods and compositions for non-viral gene therapy for treatment of hyperproliferative diseases
02/20/2002EP1142578A4 Method for producing an antitumoral agent and antitumoral agent thus obtained
02/20/2002EP0909182B1 Method for producing chlorins and bacteriochlorins containing polyether
02/20/2002EP0889898B1 Morpholinyl anthracycline derivatives
02/20/2002EP0772441B1 Use of a progesterone antagonist and of a gestagen for the treatment of endometriosis or leiomyomata uteri
02/20/2002EP0730447B1 Fatty acid delivery system
02/20/2002CN1336935A Compositions and methods for WT1 specific immunotherapy
02/20/2002CN1336928A Cytotoxic alkaloid derivatives including asmarine A and B isolated from a sponge
02/20/2002CN1336921A Fused ring heteroaryl and heterocyclic compounds which inhibit leukocyte adhesion mediated by VLA-4
02/20/2002CN1336828A Composition and method for the enhancement of the efficacy of drugs
02/20/2002CN1336386A Giant web bombinator polypeptide and its prepn. and pharmaceutical application
02/20/2002CN1336384A Giant web bombinator skin peptide and its prepn. and pharmaceutical application
02/20/2002CN1336382A Endothelial cell growth resisting engineered protein
02/20/2002CN1336381A Trichosanthin mutant and its prepn.
02/20/2002CN1336380A Anticancer polypeptide
02/20/2002CN1336367A Mercaptoone and mercaptol, and prepn. process therefor
02/20/2002CN1336235A Health-care products for regulating immunological function and delaying senility
02/20/2002CN1336232A Biological product for life-prolonging
02/20/2002CN1336230A Cancer preventing and treating Chinese herbal medicine and its prepn. process
02/20/2002CN1336229A Tumor treating antiphlogistic medicine liquid
02/20/2002CN1336223A Cancer treating traditional Chinese medicine
02/20/2002CN1336186A Antineoplastic functional water containing natural medicine component and its compounding process
02/20/2002CN1079397C 4-(benzo-1,3-dioxolyl)-pyrrolidine-3-carboxylic acid derivatives as endothelin antagonists
02/20/2002CN1079390C Propynyl or dienyl diaromatic compounds
02/20/2002CN1079265C Lucid ganoderma oral liquid and prepn. process
02/20/2002CN1079252C Medicine for treating cancer
02/20/2002CN1079250C Traditional Chinese medicinal prescription for treating liver cancer
02/20/2002CN1079247C Application of the root of Tianqiaomai for prepn. of medicine for treating leukemia, and Traditional Chinese medicine contg. same
02/19/2002US6348602 Cyclic AMP-specific phosphodiesterase inhibitors
02/19/2002US6348587 Purine or pyrimidine base derivatives; anticancer, antitumor and antiproliferative agents; treating hiv and hepatitis
02/19/2002US6348583 Nucleobase containing polythioethers synthesized on polyethylene glycol, succinic anhydride and propylamine modified glass; nucleic acid mimetics
02/19/2002US6348582 Prokaryotic polynucleotides polypeptides and their uses
02/19/2002US6348467 Antitumor agent from animal extracts
02/19/2002US6348446 Harvesting hematopoietic cells from mammal expressing cd77.sup.+ cells, treating cells with lethal dose of unconjugated shiga-toxin or shiga-like toxin-1 for sufficient time to kill cd77.sup.+ cells, thus purging from population
02/19/2002US6348352 Purging tumor cells from a hematopoietic progenitor cell population by introducing a stable tumor suppressor gene into a heterogeneous cell population and selectively transducing phenotypically hyperproliferative cells
02/19/2002US6348351 Tie receptor tyrosine kinase ligand homologues
02/19/2002US6348312 Oligonucleotide having length of 6-100 nucleotides, wherein at least one non-terminal pyrimidine nucleoside is modified, and also 5' and/or 3' ends are modified, by replacement of 3' and/or 5' phosphodiester bridge by phosphorothioate bridge
02/19/2002US6348194 Tumor specific internalizing antigens and methods for targeting therapeutic agents
02/19/2002US6348184 Contacting inert support material with aqueous solution of radioactive salt of phosphoric acid, whereby radioactive salt is adsorbed on support material and converting salt to corresponding radioactive salt of pyrophosphoric acid
02/19/2002US6347443 Method of making a hollow-tube precursor brachytherapy device
02/19/2002CA2023630C Use of toremifene and its metabolites for the reversal of multidrug resistance of cancer cells against cytotoxic drugs
02/19/2002CA2023246C Mutants of human interleukin-3
02/18/2002CA2354653A1 Peptide mutant of human erab/hadh2, its x-ray crystal structure, and materials and method for identification of inhibitors thereof
02/14/2002WO2002012900A1 Identification of viral agents in breast ducts and antiviral therapy therefore
02/14/2002WO2002012565A1 Association of sim2 with cancer
02/14/2002WO2002012537A2 Mutant trichosanthin
02/14/2002WO2002012534A2 Bio-intermediates for use in the chemical synthesis of polyketides
02/14/2002WO2002012524A2 Adenovirus e1b-55k single amino acid mutants and methods of use
02/14/2002WO2002012506A1 Lactobacillus rhamnosus polynucleotides, polypeptides and methods for using them
02/14/2002WO2002012502A2 Anti-tnf antibodies, compositions, methods and uses
02/14/2002WO2002012501A2 Anti-dual integrin antibodies, compositions, methods and uses
02/14/2002WO2002012496A1 P53-dependent novel apoptosis-associated protein and method of screening apoptosis controlling agent
02/14/2002WO2002012467A2 Drug metabolizing enzymes
02/14/2002WO2002012461A2 Regulation of human membrane-type serine protease
02/14/2002WO2002012458A1 A new polypeptide-human non-integration protein-metalloprotease 11.11 and the polynucleotide encoding it
02/14/2002WO2002012457A1 A new polypeptide-human protein phosphatase 13.31 and the polynucleotide encoding it
02/14/2002WO2002012447A2 Isolation and use of solid tumor stem cells